Pharmaceuticals, Biotechnology and Life Sciences
BerGenBio will have two presentations to highlight its Phase II clinical trial with bemcentinib and Merck’s anti-PD-1 therapy Keytruda in patients with advanced non-small cell lung cancer (NSCLC), which showed promising clinical activity overall.
BergenBio said Tuesday that preclinical data strengthen bemcentinib’s potential in reversing tumour-mediated immunosuppression and therapy resistance, ina presentation by its academic collaborators at the American Association for Cancer Research (AACR) Annual Meeting 2019.
BerGenBio started testing has started testing anti-AXL therapeutic monoclonal antibody BGB149 with healthy volunteers in its fully own Phase I clinical trial.
BerGenBio ASA has been dosed the first patient with bemcentinib, in an investigator-initiated phase II trial, sponsored by GWT-TUD GmbH, a specialist cancer clinical research institution associated with the University of Dresden, Germany.